公开(公告)号：US20170071903A1

公开(公告)日：2017-03-16

申请号：US15123476

申请日：2015-03-02

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro FUNAHASHI ,  Bruce A. Littlefield ,  Toshimitsu UENAKA

IPC: A61K31/357 ,  A61K45/06 ,  A61K31/436

CPC classification number: A61K31/357 ,  A61K31/436 ,  A61K31/675 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods for treating cancer (e.g., breast cancer, lung cancer, pancreatic cancer, primitive neuroectodermal tumors, lung cancer, ovarian cancer, endometrial cancer, pharyngeal cancer, esophageal cancer, and sarcoma) in a subject (such as an human patient) in need thereof by administering eribulin (e.g., eribulin mesylate, i.e., E7389, Halaven) in combination with one or more mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus, ridaforolimus, and temsirolimus), and kits therefor are provided.

Abstract translation: 在需要的受试者（例如人类患者）中治疗癌症（例如乳腺癌，肺癌，胰腺癌，原始神经外胚层肿瘤，肺癌，卵巢癌，子宫内膜癌，咽癌，食管癌和肉瘤）的方法 通过与一种或多种雷帕霉素（mTOR）抑制剂（例如依维莫司，阿糖胞苷和替西罗莫司）的哺乳动物靶标组合​​施用eribulin（例如，甲磺酸eribulin，即E7389，Halaven）及其试剂盒。

公开(公告)号：US20210123919A1

公开(公告)日：2021-04-29

申请号：US17052133

申请日：2019-05-13

Applicant: Merck Sharp & Dohme Corp. ,  Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro FUNAHASHI ,  Kotaro KODAMA ,  Ryo DAIRIKI ,  Yukinori MINOSHIMA

IPC: G01N33/574 ,  A61K31/47 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a combination therapy comprising lenvatinib compound and a PD-1 antagonist. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing cancer.

公开(公告)号：US20220409724A1

公开(公告)日：2022-12-29

申请号：US17772468

申请日：2020-10-28

Applicant: Eisai R&D Management Co., Ltd. ,  Merck Sharp & Dohme Corp. ,  MSD International GmbH

Inventor： Yoichi OZAWA ,  Yasuhiro FUNAHASHI ,  Yu KATO

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/47 ,  A61K31/53

Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.

公开(公告)号：US20180071247A1

公开(公告)日：2018-03-15

申请号：US15554540

申请日：2016-03-03

Applicant: MERCK SHARP & DOHME CORP. ,  Eisai R&D Management Co., Ltd.

Inventor： Junji MATSUI ,  Gursel AKTAN ,  Vassiliki KARANTZA ,  RuiRong YUAN ,  Yasuhiro FUNAHASHI ,  Erhan BERRAK

IPC: A61K31/357 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  A61K9/00

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.